Cequent Raises Series A

Cequent Pharmaceuticals, a Cambridge, Mass.-based developer of RNAi-based treatments, has raised $9 million in Series A funding. Participants included Ampersand Ventures, Nexus Medical Partners, Pappas Ventures and Novartis Option Fund. www.cequentpharma.com